Thomas P. Mathers

Chief Executive Officer

Tom joined CoLucid as Chief Executive Officer in 2011. He has more than twenty two years of executive management experience in the life sciences and medical device industry. Mr. Mathers also serves on the Board of Directors for the Biotechnology Industry Organization (BIO), and as founder and chairman of Déclion Holdings and its affiliates.

Prior to CoLucid, Tom served as president and CEO of Peptimmune, Inc.; president and CEO of Cell Based Delivery; vice president and general manager of Cardion AG; vice president of Strategic Development at Genzyme; and held management positions at Snowden-Pencer and Pfizer, Inc.

Tom holds several patents and patents pending and earned his BS in Engineering from the United States Military Academy at West Point, where he was a Dean's List student and three-year starter on the football team as a defensive end. From 1988 to 1991 he served as captain in the United States Army and was awarded several medals for his services as an AH-64 Apache helicopter pilot in the Gulf War in the XVIII Airborne Corps.

Art Pappas


Art has over 30 years of operating experience as a pharmaceutical and biotechnology industry executive, and venture capital investor in life science companies. Art founded Pappas Capital in 1994, and over the past two decades the firm has managed $450 million in capital and invested in more than 70 life science companies. In addition, Pappas manages the Chiesi Ventures Fund, which invests in companies developing medicines for rare and orphan diseases. 

Art currently serves as a director of CoLucid Pharmaceuticals, for which he is chairman and also served as the founding CEO, Afferent Pharmaceuticals and Aura Biosciences. He also serves as a board observer for Real Endpoints. Prior to founding Pappas Capital, Art held senior level leadership positions at several multinational pharmaceutical companies for which he was responsible for the development, licensing and launch of a number of global products. He was an executive member of the board of directors of Glaxo Holdings plc (NYSE: GLX, now GSK), and served as Glaxo’s chief executive responsible for international operations including research, development and manufacturing. Art previously was Vice President of Commercial Operations for Abbott International, and he held various executive and general management positions with Merrell Dow Pharmaceuticals and the Dow Chemical Company, in the United States and internationally. He previously served on the boards of Chimerix (NASDAQ: CMRX), Quintiles Transnational Corp. (NASDAQ: QTRN now NYSE: Q), TYRX (acquired by Medtronic in 2014), Syntonix Pharmaceuticals (acquired by Biogen IDEC in 2007), LEAD Therapeutics (acquired by BioMarin in 2010), CardioDx, and Embrex (NASDAQ: EMBX), which was acquired by Pfizer. He also served as a board observer at Plexxikon, which was sold to Daiichi Sankyo in 2011. 

Art is a member of the Board of Directors of the National Venture Capital Association and the North Carolina Biotechnology Center, where he was the past chair. He is also a member of the Board of Directors of the Medical University of South Carolina Foundation for Research Development, the Board of Trustees of The Wistar Institute, a National Cancer Institute center, the Board of Advisors of the Duke Cancer Institute, the CEO Roundtable on Cancer, and BayHelix, an organization of global life science community leaders. Art is a decorated Vietnam veteran, having served as an officer in the US Army 101st Airborne Division and 2nd PSYOP Airborne Group JFK Special Warfare Center. Art received a BS in biology from Ohio State University and an MBA in finance from Xavier University.

Martin Edwards, BSc (Hons), MB.ChB (Hons), MRCP, MRCGP (Dist), FFP


Martin is Senior Partner at Novo Ventures, the venture capital arm of Novo A/S. He is Chairman of Vantia Ltd, KalVista Pharmaceuticals Ltd, and Epsilon 3 Bio Ltd and a Director on the boards of CoLucid Pharmaceuticals, Inc., Nuvelution Pharma Inc., Tarsa Therapeutics Inc. and Acacia Pharma Ltd. 

Prior to this, Martin was CEO of ReNeuron Ltd from 1998 to 2003 taking the company public in 2001. 

He was world-wide head of drug development for Novo Nordisk from 1994 to 1998, Senior Vice President at Novo Nordisk (USA) from 1992 to 1994 and CMO/Vice President at Zymogenetics from 1989 to 1992. 

Martin trained in physiology and medicine in Manchester UK and in business at Warwick University. In 2009 Martin was made Adjunct Professor at CBS Executive in Copenhagen.

Alison Lawton


Alison Lawton is currently the Chief Operating Officer (COO) at Aura Biosciences and prior to this was Chief Operating Officer of OvaScience, Inc. Previously she was with Genzyme Corp. (now NYSE: SNY) for 21 years where she had a number of roles including Senior Vice President and General Manager of the Sanofi Biosurgery Business Unit and Global Head of Market Access at Genzyme which included Regulatory Affairs, Global Health Outcomes and Strategic Pricing, Global Public Policy, and Global Product Safety & Risk Management. Ms. Lawton spent 8 years in the UK at Parke-Davis and is past President and Chair of the Board of Regulatory Affairs Professional Society. Ms. Lawton serves on the board of ProQR Therapeutics (NASDAQ: PRQR), Verastem Inc. (NASDAQ: VSTM) and was previously director of Cubist Pharmaceuticals until its acquisition by Merck &Co., Inc. in 2015 (NASDAQ: CBST)

Mark Corrigan, MD


Dr. Corrigan has been elected as a class II director of the Company with a term expiring at the annual meeting of stockholders to be held in 2017. Dr. Corrigan serves as Chairman of the Compensation Committee. Dr. Corrigan serves as a director of EPIRUS Biopharmaceuticals, Inc., and Cardiome Pharma Corp. Previously, he served as president and chief executive officer of Zalicus, Inc., a predecessor of EPIRUS Biopharmaceuticals, from January 2010 until the two companies merged in July 2014. Dr. Corrigan was Executive Vice President, Research & Development of Sunovion Pharmaceuticals Inc. (formerly Sepracor Inc.) from April 2003 until December 2009. Prior to joining Sunovion Pharmaceuticals, he spent 10 years with Pharmacia & Upjohn, Inc., most recently as Group Vice President of Global Clinical Research and Experimental Medicine. Prior to joining the pharmaceutical industry, Dr. Corrigan spent five years in academic research at the University of North Carolina Medical School, focusing on psychoneuroendocrinology. Dr. Corrigan served on the board of directors of Cubist Pharmaceuticals, Inc. (acquired by Merck & Co., Inc.), from 2008 until 2015, and Avanir Pharmaceuticals (acquired by Otsuka), from 2014 until 2015.

Luc Marengere, PhD


Dr. Marengere is Managing Partner of TVM Life Science Venture VII. He oversees the establishment of the new Canadian operations and the North American investment strategy as well as deal sourcing and execution. Luc is responsible for ongoing relationships with certain Canadian LPs as well as Korean investors Bukwang Pharma and Quad Investment Management located in Seoul. 

Dr. Marengere joined TVM Capital in 2012 and has 20 years of venture capital experience in Canada and the U.S. Prior to joining TVM, Dr. Marengere was a Managing General Partner with VG Partners where he successfully founded and oversaw the operations and investments of the VG Advanced Life Sciences Fund (VG ALSF).Luc is currently a Director on the Board of US-based Colucid (NASDAQ – “CLCD”), UK-based Ixchelsis and Canadian-based PRCL Research Inc as well as Modulate Therapeutics Inc. Luc was a Director on the Boards of a number of companies including Trillium Technologies Inc., (Toronto, ON – NASDAQ – “TRIL”); Cytochroma Inc., (Toronto, ON – sold to Opko Health); Aegera Therapeutics, Inc. (Montréal, QC – sold to Pharmascience); Cita Neuropharma (Toronto, ON - sold to Vernalis Plc, UK) and lastly Argos Therapeutics Inc., (Durham, NC –NASDAQ – “ARGS”). Luc also invested in VisualSonics, Inc. (Toronto, ON - sold to SonoSite). Prior to joining TVM Capital, Luc founded the life science practice and team within VG Partners and raised more than $230M for the first fully dedicated life science fund, VG Advanced Life Science Fund. Luc has worked as a Director focused on making venture investments in the life science sector while with CDP Capital – Technology Ventures and MDS Capital Corp. 

Prior to his venture capital career, he conducted commercially-oriented research in the fields of immunology and oncology while at Amgen. He holds a Ph.D. from University of Toronto’s department of Medical Biophysics and Molecular Genetics, A Master’s degree of Science from Queen’s University and he graduated Magna Cum Laude from University of Ottawa.

Marvin White


Mr. White has served as a director for CoLucid Pharmaceuticals since July 2015 and is the chairman of the company’s audit committee for the Board of Directors. Mr. White serves as the president and chief executive officer of The MLW Advisory Group, LLC, a management advisory company targeting the needs of healthcare and related companies. From 2008 to 2014, Mr. White served as system vice president and chief financial officer of St. Vincent Health, and was responsible for finance, accounting, patient financial services and managed care for all 19 hospitals and 36 joint ventures. Prior to joining St. Vincent Health in 2008, Mr. White was executive director and chief financial officer of Lilly USA, a subsidiary of Eli Lilly and Company, where he also held leadership positions in Corporate Finance and Investment Banking in the Corporate Strategy Group. He serves on the boards of OneAmerica Financial Partners, Emergent Biosolutions, WP Glimcher, and has been active with Saving Orphans through Healthcare and Outreach (SOHO), Atlanta National Association of Corporate Directors (NACD) and with the United Way. Mr. White earned his B.A. in Accounting from Wilberforce University, and an M.B.A. in Finance from Indiana University.